[Interleukin-1-mediated diseases]

Area of Science:

• Immunology
• Inflammation Biology
• Genetics

Context:

• Interleukin-1 (IL-1) mediated diseases are characterized by excessive IL-1 beta production.
• These conditions encompass a spectrum from rare hereditary autoinflammatory syndromes to common diseases like gout and type 2 diabetes.
• Delayed recognition and treatment can lead to severe long-term complications, including amyloidosis.

Purpose:

• To review the pathogenic mechanisms, diagnostic approaches, and therapeutic strategies for IL-1 mediated inflammatory diseases.
• To highlight recent advancements in the management of these conditions.
• To underscore the broad clinical relevance of IL-1 dysregulation.

Summary:

• IL-1 mediated diseases result from overproduction of IL-1 beta, causing symptoms such as arthritis, fever, and inflammation.
• While some are rare hereditary conditions (e.g., cryopyrin-associated periodic fever syndromes), IL-1 also drives common diseases like gout and type 2 diabetes.
• Modern treatments include monoclonal antibodies targeting IL-1 and IL-1 receptor antagonists, significantly improving patient outcomes, especially when initiated early.

Impact:

• Improved understanding of IL-1's role in both rare and common inflammatory diseases.
• Advances in diagnostics and therapeutics offer new hope for patients with debilitating conditions.
• Early intervention strategies can prevent severe long-term complications and enhance quality of life.